Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Dermatologic 1

Conditions

Stomach Neoplasms 1Melanoma 1Lethal Congenital Contracture Syndrome 2 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 30Nivolumab 29Specimen Handling 25Ipilimumab 19Magnetic Resonance Spectroscopy 17Biopsy 11CTLA-4 Antigen 9Cyclophosphamide 8Opdualag 7relatlimab 6Paclitaxel 6trametinib 5fludarabine 5cemiplimab 5binimetinib 5Carboplatin 5fludarabine phosphate 4dabrafenib 4avelumab 4atezolizumab 4HhAntag691 4lifileucel 3capivasertib 3aldesleukin 3X-Rays 3Temozolomide 3Taxes 3Surgical Procedures, Operative 3Standard of Care 3Radiotherapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Paroxetine × Dermatologic × 30 days × Clear all
NCT07070232 2026-05-22

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

BioNTech SE

Phase 1/2 Recruiting
980 enrolled
DermatologicGastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡